91076-95-8

Usage

Uses

Used in Pharmaceutical Synthesis:
3-AMINO-5-(4-BROMOPHENYL)THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER is used as an intermediate in the synthesis of pharmaceuticals for its potential applications in medicinal chemistry.
Used in Agrochemical Synthesis:
3-AMINO-5-(4-BROMOPHENYL)THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products.
Used in Organic Synthesis:
3-AMINO-5-(4-BROMOPHENYL)THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER is used as a building block in the preparation of various heterocyclic compounds, which are important in the field of organic synthesis.

InChI:InChI=1/C12H10BrNO2S/c1-16-12(15)11-9(14)6-10(17-11)7-2-4-8(13)5-3-7/h2-6H,14H2,1H3

Upstream product

• 78583-87-6 (E)-3-(4-Bromo-phenyl)-3-chloro-acrylonitrile 
• 2365-48-2 Methyl thioglycolate 
• 99-90-1 para-bromoacetophenone 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 649757-40-4 6-(4’-bromophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione 
• 1170196-31-2 C₁₉H₁₇NO₄S₃ 
• 1170194-00-9 C₂₁H₂₀N₂O₄S₂ 
• 1170196-21-0 C₁₉H₁₇NO₄S₃ 
• 1435106-90-3 C₂₆H₂₅N₃O₄S₂ 
• 1435106-15-2 C₂₉H₂₉N₃O₄S₂ 
• 1435105-33-1 C₂₃H₂₅N₃O₄S₂ 
• 1435104-57-6 C₂₀H₂₁N₃O₄S₂ 
• 1435103-83-5 C₂₁H₂₀N₂O₄S₂ 
• 1435101-63-5 C₂₀H₁₉NO₄S₃ 
• 1435100-70-1 C₂₀H₁₉NO₄S₃ 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.

One-pot synthesis of 2-substituted thieno[3,2-b]indoles from 3-aminothiophene-2-carboxylates through in situ generated 3-aminothiophenes

A convenient protocol for one-pot synthesis of thieno[3,2-b]indoles, bearing aromatic, thien-2-yl or styryl fragments at C-2 position, from easily accessible 5-substituted 3-aminothiophene-2-carboxylates using the Fischer indolization reaction, was develo

Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: Structure-based optimization of a virtual screening hit

Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit can

Combining in silico and biophysical methods for the development of pseudomonas aeruginosa quorum sensing inhibitors: An alternative approach for structure-based drug design

The present work deals with the optimization of an inhibitor of PqsD, an enzyme essential for Pseudomonas aeruginosa quorum sensing apparatus. Molecular docking studies, supported by biophysical methods (surface plasmon resonance, isothermal titration cal

Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1

The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pKas and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.